FROM SCIENCE TO BUSINESS
HYBRID is born from the desire to gather the whole ecosystem of innovation including academic researchers, start-ups and industries with the aim to break down barriers between their respective approaches.
We do believe that this event is a true opportunity to foster synergies, favor public-private partnerships and thus faster develop innovative health products, i.e. from the idea to making it available to patients.
3 TYPOLOGIES OF ACTORS
Over a dozen industrial teams from international pharmaceutical companies working on the thematic of the event will take part in the debates and B2B meetings. These teams will be composed of experts and decision-makers from medical, business development, market access or clinical study departments.
PUBLIC RESEARCH TEAMS
Over a dozen of public research teams coming from French laboratories and institutes of excellence are selected by the Alliance AVIESAN to attend this event. These top talented scientists are selected according to their worldwide renown on the thematic, their historic of collaboration with start-ups or industries and their wish to develop new partnerships.
About ten promising French start-ups will also attend this event. They are selected after a three-step process including a call for expression of interest, an evaluation by a jury composed of researchers, investors and industrials, and a final audition session.